Anita Grigoriadis is the Non-Clinical Deputy Head for the Breast Cancer Now Unit, and a Reader in Cancer Bioinformatics at King’s College London, London UK. After finishing her degree at the Institute of Molecular Pathology, University of Vienna (Austria), Anita pursued a joint PhD between the Ludwig Institute for Cancer Research, London UK and Faculty of Natural Sciences, Salzburg Austria. Anita conducted her postdoctoral training on breast cancer genomics with Professor Alan Ashworth at Breakthrough Breast Cancer Centre (London). In 2008, she joined the Breast Cancer NOW Unit (formerly Breakthrough Breast Cancer Research) at King’s College London, under the leadership of Professor Andrew Tutt, and started her own team in 2013. Currently, Anita is a committee member of the CRUK City of London Centre Executive Board, The Clinical Trial Pathology Advisory Group of the Cellular Molecular Pathology (NCRI programme), and recently the Research Subcommittee of the Pathological Society.
Ian Pike’s biography Ian Pike is the Chief Scientific Officer at Proteome Sciences and has 30 years’ experience working in the diagnostics and biotechnology sectors. Having gained a PhD in Medical Microbiology, he joined Welcome Diagnostics as a research group leader and spent 8 years working on new diagnostic assays, particularly for hepatitis. In December 1999, he joined the Technology Transfer Office of the UK Medical Research Council with responsibility for patents and commercialization of a wide portfolio of technologies related to the biomedical sector. Ian also worked for Cancer Research Ventures managing intellectual property and performing business development activities in Europe and the USA. Since joining Proteome Sciences in 2002 he has held a number of roles covering intellectual property management, business development, operational management and is now focused on leading the Company’s scientific strategy to offer clients a flexible, high quality service.
Nagy is the CMO of MiNA Therapeutics. For over three decades Nagy has been at the forefront of clinical research and clinical practice in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. Currently, he is driving the development of an saRNA drug (a new class of medicines) which is currently being trialed in patients with liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, ClinicalTrials.gov ID NCT02716012) and in a second trial in patients with solid tumours (TIMEPOINT study, ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan. He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Previously Nagy was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018). Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London.